{"id":"https://openalex.org/W2535758366","doi":"https://doi.org/10.1182/blood.v104.11.1403.1403","title":"Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin\u2019s Lymphoma with Primary Resistance to or Progression Following Rituximab.","display_name":"Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin\u2019s Lymphoma with Primary Resistance to or Progression Following Rituximab.","publication_year":2004,"publication_date":"2004-11-16","ids":{"openalex":"https://openalex.org/W2535758366","doi":"https://doi.org/10.1182/blood.v104.11.1403.1403","mag":"2535758366"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v104.11.1403.1403","doi":"https://doi.org/10.1182/blood.v104.11.1403.1403","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v104.11.1403.1403","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065296584","display_name":"Ayad M Al-Katib","orcid":"https://orcid.org/0000-0002-5684-948X","observed_orcids":["https://orcid.org/0000-0002-5684-948X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ayad Al-Katib","raw_affiliation_strings":["Hematology/Oncology, Van Elslander Cancer Center, Grosse Pointe Woods, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Van Elslander Cancer Center, Grosse Pointe Woods, MI, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113876581","display_name":"David Duane Hurd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405269449","display_name":"Wake Forest University Health Sciences","ror":"https://ror.org/046r1r105","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]},{"id":"https://openalex.org/I47251452","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724","country_code":"US","type":"education","lineage":["https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David D. Hurd","raw_affiliation_strings":["Hematology/Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA","institution_ids":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110302696","display_name":"Robert N. Raju","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Raju","raw_affiliation_strings":["Hematology/Oncology, Dayton Oncology & Hematology, Kettering, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Dayton Oncology & Hematology, Kettering, OH, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103699184","display_name":"Joe Stephenson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283654650","display_name":"Prisma Health","ror":"https://ror.org/03n7vd314","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1283654650"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joe Stephenson","raw_affiliation_strings":["Hematology/Oncology, Cancer Center of the Carolinas, Greenville, SC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Cancer Center of the Carolinas, Greenville, SC, USA","institution_ids":["https://openalex.org/I1283654650"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francis Giles","raw_affiliation_strings":["Leukemia, MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006368558","display_name":"Eric Haltom","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Haltom","raw_affiliation_strings":["Clinical Research, Point Therapeutics, Inc, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, Point Therapeutics, Inc, Boston, MA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050848933","display_name":"Margaret J. Uprichard","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Margaret J. Uprichard","raw_affiliation_strings":["Clinical Research, Point Therapeutics, Inc, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, Point Therapeutics, Inc, Boston, MA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.2276,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.64936471,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"104","issue":"11","first_page":"1403","last_page":"1403"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.013000000268220901,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pt-100","display_name":"Pt(100)","score":0.8980000019073486},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.9639999866485596},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.7630000114440918},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/dipeptidyl-peptidase-inhibitors","display_name":"dipeptidyl peptidase inhibitors","score":0.9049999713897705},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.7279999852180481},{"id":"https://openalex.org/keywords/cytokines-and-chemokines","display_name":"cytokines and chemokines","score":0.7889999747276306},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4699999988079071},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.515999972820282},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.47200000286102295},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.898910403251648},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.826945424079895},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6212166547775269},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5864092707633972},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5645343661308289},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5499111413955688},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.536099910736084},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4176989197731018},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34637850522994995}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v104.11.1403.1403","doi":"https://doi.org/10.1182/blood.v104.11.1403.1403","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v104.11.1403.1403","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8600000143051147}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2594237324","https://openalex.org/W2225659592","https://openalex.org/W2583152252","https://openalex.org/W2557271465","https://openalex.org/W2143161378","https://openalex.org/W2570495056","https://openalex.org/W4406746509","https://openalex.org/W2091210765","https://openalex.org/W1974307608","https://openalex.org/W1969589284"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Talabostat":[2,22,46,379],"(PT-100),":[3],"an":[4],"orally":[5],"available":[6],"inhibitor":[7],"of":[8,25,53,71,98,116,249,358,444,447,462],"dipeptidyl":[9],"peptidases,":[10],"is":[11,60],"in":[12,29,75,269,287,295,312,348,355,418,426,438],"Phase":[13,62],"2":[14,247],"studies":[15,443],"for":[16,110,309],"B-cell":[17],"malignancies":[18],"and":[19,27,32,37,69,73,119,125,135,143,147,162,174,179,205,235,246,265,336,363,399,414,431,452],"solid":[20],"tumors.":[21],"increases":[23],"production":[24],"cytokines":[26,313,413],"chemokines":[28,120,415],"lymph":[30],"nodes":[31],"spleen,":[33],"stimulating":[34],"both":[35],"adaptive":[36],"innate":[38],"immune":[39,454],"responses":[40],"(Adams":[41],"S,":[42],"Cancer":[43],"Research,":[44],"2004;64:5471).":[45],"may":[47],"thus":[48],"enhance":[49],"the":[50,67,165,196,305,356,445,453,460],"antibody-dependent":[51],"cytotoxicity":[52],"MAbs":[54],"such":[55],"as":[56],"rituximab.":[57,87,117,385],"Methods:":[58],"This":[59],"a":[61,296],"1":[63,202],"study":[64],"to":[65,436,458],"evaluate":[66],"safety":[68],"activity":[70],"talabostat":[72,99],"rituximab":[74],"patients":[76,194,271,369,439],"with":[77,184,370,384,406,440],"indolent":[78],"NHL":[79,185],"who":[80],"did":[81,302],"not":[82,303],"respond":[83],"or":[84,104,187,342],"progressed":[85],"following":[86,113,320],"Rituximab":[88],"375mg/m2":[89],"was":[90,139,285,293,346,373],"administered":[91,108,382],"weekly":[92],"x":[93],"4.":[94],"Total":[95],"daily":[96],"doses":[97,319],"400\u03bcg":[100],"(n=6),":[101],"600\u03bcg":[102],"(n=3),":[103],"800\u03bcg":[105],"(n=6)":[106],"were":[107,121,150,158,169,267,276,315,353,390,408,416,423,429,434],"BID":[109],"6":[111,126],"days":[112],"each":[114],"dose":[115],"Cytokines":[118],"assessed":[122],"pre-,":[123],"2,":[124],"hours":[127],"post-talabostat":[128],"on":[129,171],"Days":[130,172],"1,":[131],"6,":[132],"13,":[133],"20,":[134],"27.":[136],"Flow":[137],"cytometry":[138],"performed":[140,151,170],"at":[141,152,200,203,207,211,272,299,375,410],"baseline":[142],"Day":[144,340,376],"28.":[145,377],"Clinical":[146],"laboratory":[148],"evaluations":[149],"specified":[153],"times.":[154],"Adverse":[155],"events":[156,248,275,404],"(AEs)":[157],"graded":[159],"per":[160],"NCI-CTC":[161],"recorded":[163],"throughout":[164],"study.":[166],"Disease":[167],"assessments":[168],"28":[173,341],"84.":[175],"Results:":[176],"11":[177],"men":[178],"4":[180,199,206],"women":[181],"aged":[182],"48\u201382":[183],"(n=10)":[186],"SLL/CLL":[188],"(n=5)":[189],"have":[190,217],"been":[191,218],"treated.":[192],"9":[193],"completed":[195],"28-day":[197],"study:":[198],"400\u03bcg,":[201],"600\u03bcg,":[204],"800\u03bcg.":[208],"Enrollment":[209],"continues":[210],"400\u03bcg/day.":[212],"The":[213,386],"most":[214,349,387,419],"frequent":[215,388],"AEs":[216,389],"edema":[219],"(67%),":[220],"nausea":[221],"(47%),":[222],"dizziness":[223],"(40%),":[224],"hypotension":[225],"(33%),":[226,228,230,232],"fatigue":[227],"vomiting":[229],"constipation":[231],"thrombocytopenia":[233,250],"(27%),":[234],"weight":[236,400],"gain":[237],"(27%).":[238],"Grade":[239,252,402],"3":[240,253,403],"toxicities":[241],"include:":[242],"dizziness,":[243,393],"myopathy":[244],"(400\u03bcg/day),":[245],"(600\u03bcg/day).":[251],"peripheral":[254],"edema,":[255,391],"myalgia,":[256],"dehydration,":[257],"electrolyte":[258],"imbalance,":[259],"hypereosinophilia,":[260],"elevated":[261],"CPK":[262],"(primarily":[263],"CK-MM),":[264],"rhabdomyolysis":[266,407],"seen":[268,286,294,354],"2/6":[270],"800\u03bcg/day;":[273],"these":[274],"DLTs.":[277],"One":[278],"partial":[279],"response":[280],"(PR)":[281],"lasting":[282],"7":[283],"months":[284],"one":[288],"patient":[289,298],"(800\u03bcg/day).":[290],"A":[291],"PR":[292],"second":[297],"800\u03bcg/day":[300],"but":[301],"meet":[304],"strict":[306],"NCI-WG":[307],"criteria":[308],"response.":[310],"Elevations":[311],">ULN":[314],"reported":[316],"across":[317],"all":[318,367],"talabostat:":[321],"G-CSF":[322],"(13/15),":[323],"IL-1\u03b2":[324],"(10/15),":[325],"IL-2":[326],"(7/15),":[327],"IL-6":[328],"(8/15),":[329,331],"IL-8":[330],"IL-10":[332],"(11/15),":[333,335],"TNF-\u03b1":[334],"IFN-\u03b3":[337],"(3/15).":[338],"At":[339],"early":[343],"termination,":[344],"CD20":[345],"decreased":[347],"(12/15)":[350],"patients.":[351,420],"Increases":[352,425],"percentage":[357],"CD3":[359],"(12/15),":[360],"CD3/4":[361],"(11/15)":[362],"CD3/8":[364],"(9/15).":[365],"In":[366],"5":[368],"SLL/CLL,":[371],"CD5+/CD20+":[372,432],"<2%":[374,437],"Conclusion:":[378],"can":[380],"be":[381],"safely":[383],"nausea,":[392],"hypotension,":[394],"fatigue,":[395],"vomiting,":[396],"constipation,":[397],"thrombocytopenia,":[398],"gain.":[401],"consistent":[405],"DLTs":[409],"800\u03bcg/day.":[411],"Key":[412],"upregulated":[417],"Two":[421],"PRs":[422],"reported.":[424],"T-cell":[427],"subsets":[428],"observed":[430],"cells":[433],"reduced":[435],"SLL/CLL.":[441],"Further":[442],"mechanism":[446],"interactions":[448],"between":[449],"talabostat,":[450],"rituximab,":[451],"system":[455],"are":[456],"needed":[457],"maximize":[459],"benefit":[461],"this":[463],"new":[464],"agent.":[465]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-10-28T00:00:00"}